The opioid crisis continues to escalate. In 2017, the U.S. declared it a public health emergency. Since then, annual opioid overdose deaths have climbed past 80,000, with roughly 90% involving synthetic opioids like fentanyl. Researchers have been exploring whether cannabis could play a role in reducing opioid dependence. The picture is complicated.

Does legalizing cannabis reduce opioid use?

Early population-level studies found that states with legal medical cannabis saw fewer opioid overdose deaths. But when researchers extended the timeline, those gains didn't hold. Whatever initial benefit existed appeared to be short-lived.

States that legalized recreational cannabis saw an initial 7.6% drop in opioid-related ER visits compared to non-legal states, but that difference disappeared within six months.

Some studies show patients who use cannabis alongside prescription opioids report using fewer opioids. But in rigorously controlled clinical trials, consistent reductions haven't materialized, even though most patients say they prefer cannabis over opioids for pain management.

What the lab research shows

There are currently 15 ongoing clinical trials investigating cannabis and opioid need. The interest is driven by animal studies showing clear interactions between the endocannabinoid system and the opioid system.

In rodent pain experiments, THC has consistently reduced the effective dose of morphine needed, by an average of 3.5 times across seven studies. Three mechanisms appear to drive this:

  • THC stimulates CB1 receptors, which exist in the same pain-processing brain areas as opioid receptors
  • CB1 receptors interact with opioid receptors to boost their pain-relieving effect in animal models
  • CB2 receptors can trigger the release of the body's own natural opioids

Why don't these promising animal results consistently translate to humans? One factor may be tolerance. Repeated use of high-potency THC products reduces CB1 receptor availability over time, which could undermine the synergy between the two systems. Most rodent studies are short (days), while human use is chronic (weeks or longer).

CBD and opioid dependence

Separate from THC, CBD is emerging as a research focus for people struggling with opioid use disorder. When Italy unintentionally legalized CBD-rich cannabis in 2017, researchers observed a reduction in opioid use.

Several clinical studies have found that CBD reduces cues that trigger opioid cravings and dampens the stress response that accompanies those cravings. Animal research shows CBD diminishes many of the behavioral and anxiety changes that accompany opioid withdrawal and lead to relapse. Additional clinical trials are underway.

Where things stand

There is no clear scientific consensus on whether cannabis can replace or reduce the need for opioids. The range of use patterns, product options, cannabinoid profiles, and reasons for needing pain management make this a particularly challenging research question.

What is clear: co-use of cannabis does not appear to increase opioid use, and the "gateway drug" framing is not supported by the data. Safety concerns like respiratory suppression were not worsened by cannabis co-use in the studies reviewed.

This is an active, evolving area of research. The conversation is far from settled.